Full Press Release Details
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its leadin vivodevelopment candidate, to be a transformative therapy for people living with hyperlipidemia.
The complete list of Editas Medicine presentations is below.
American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15
Oral Presentation:Title:Preclinical Development of EDIT-401, a DurableIn VivoCRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-CSession Date and Time:Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDTSession Title:Gene Therapy for Cardiovascular DiseasesPresentation Room:206ABFinal Abstract Number:380
Poster Presentations:Title:Pharmacokinetics and Pharmacodynamics ofIn VivoGene Editing Therapy for Lowering LDL-C in MiceSession Date and Time:Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDTSession Title:Thursday Poster ReceptionPresentation Room:Exhibit and Poster HallFinal Abstract Number:3423
Title:In VivoCRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease ModelSession Date and Time:Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDTSession Title:Wednesday Poster ReceptionPresentation Room:Exhibit and Poster HallFinal Abstract Number:2324
TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14
Oral Presentation:Title:Transformative LDL Cholesterol LoweringIn VivoCRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular DiseaseSession Date and Time:Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDTSession Title:mRNA & Genome Editing: Technology & Applications
94thEuropean Atherosclerosis Society (EAS) Congress, May 24-27
Oral Presentation:Title:A TransformativeIn VivoCRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human PrimatesSession Date and Time:Monday, May 25, 3:45 p.m. – 5:15 p.m. EET/9:45 a.m. – 11:15 a.m. EDTSession Title:New Pathways for Lipid and Lipoprotein MetabolismPresentation Room:Nana HallFinal Abstract Number:159
Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences.
About Editas MedicineAs a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformativein vivomedicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precisionin vivogene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.